文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

[Secondary choroidal neovascularization-Really so common?].

作者信息

Brocks Ulrike, Ziegler Martin, Lange Clemens, Altay Lebriz, Pauleikhoff Laurenz

机构信息

Klinik für Augenheilkunde, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.

Augenzentrum am St. Franziskus Hospital, Münster, Deutschland.

出版信息

Ophthalmologie. 2025 Mar;122(3):196-200. doi: 10.1007/s00347-025-02197-8. Epub 2025 Feb 10.


DOI:10.1007/s00347-025-02197-8
PMID:39928089
Abstract

The occurrence of secondary choroidal neovascularization (CNV) is a complication in patients with chronic central serous chorioretinopathy. The diagnosis is made using multimodal imaging. The treatment usually includes intravitreal anti-vascular endothelial growth factor (VEGF) injections. A combination with photodynamic therapy can be useful; however, the response to anti-VEGF treatment is significantly reduced compared to other indications for CNV, so that an irreversible decrease of visual acuity often remains.

摘要

相似文献

[1]
[Secondary choroidal neovascularization-Really so common?].

Ophthalmologie. 2025-3

[2]
Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy.

Eye (Lond). 2016-6

[3]
ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY VERSUS PHOTODYNAMIC THERAPY IN THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO CENTRAL SEROUS CHORIORETINOPATHY.

Retina. 2018-8

[4]
Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy.

Br J Ophthalmol. 2020-7

[5]
ANTIANGIOGENICS IN CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH LASER IN CENTRAL SEROUS CHORIORETINOPATHY.

Retina. 2016-5

[6]
Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents.

Graefes Arch Clin Exp Ophthalmol. 2020-5

[7]
Optical coherence tomographic angiography of choroidal neovascularization associated with central serous chorioretinopathy.

JAMA Ophthalmol. 2015-10

[8]
Intravitreal bevacizumab to treat choroidal neovascularization following photodynamic therapy in central serous choroidopathy.

Eur J Ophthalmol. 2011

[9]
Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy.

Graefes Arch Clin Exp Ophthalmol. 2015-6

[10]
Risk Factors and Outcomes of Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy.

Sci Rep. 2019-3-8

本文引用的文献

[1]
Impact of the Valsalva manoeuvre on the choroid: A systematic review with meta-analyses.

Acta Ophthalmol. 2025-3

[2]
Three-year outcome of photodynamic therapy combined with VEGF inhibitor for pachychoroid neovasculopathy.

Graefes Arch Clin Exp Ophthalmol. 2024-10

[3]
Choroidal hyperpermeability patterns correlate with disease severity in central serous chorioretinopathy: CERTAIN study report 2.

Acta Ophthalmol. 2024-9

[4]
Clinical Landscape of Central Serous Chorioretinopathy in Germany: Retina.net CSC Registry Report Number 1.

Ophthalmologica. 2024

[5]
Choroidal Vascular Changes on Ultrawidefield Indocyanine Green Angiography in Central Serous Chorioretinopathy: CERTAIN Study Report 1.

Ophthalmol Retina. 2024-3

[6]
MULTIMODAL IMAGING FEATURES AND TREATMENT RESPONSES OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO CENTRAL SEROUS CHORIORETINOPATHY.

Retina. 2022-12-1

[7]
OCT Angiography Fractal Analysis of Choroidal Neovessels Secondary to Central Serous Chorioretinopathy, in a Caucasian Cohort.

J Clin Med. 2022-3-6

[8]
Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy.

PLoS One. 2021

[9]
An efficacy comparison of combination of different anti-vascular endothelial growth factors and photodynamic therapy in patients with pachychoroid neovasculopathy.

Int Ophthalmol. 2021-6

[10]
Treatment-naïve quiescent macular neovascularization secondary to AMD: The 2019 Young Investigator Lecture of Macula Society.

Eur J Ophthalmol. 2021-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索